Shale producer APA misses fourth-quarter profit estimates-February 2024-www.financetom.com

Shale producer APA misses fourth-quarter profit estimates

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Shale producer APA misses fourth-quarter profit estimates

Feb 26, 2025 1:52 PM

Feb 26 (Reuters) - U.S. shale producer APA Corp ( APA )

fell short of Wall Street expectations for fourth-quarter profit

on Wednesday as weak commodity prices offset a rise in

production.

The Houston-based company posted an adjusted profit of 79

cents per share for the three months ended December 31, compared

with the average analyst estimate of 97 cents, according to data

compiled by LSEG.

Previous page： RTX's GPS Ground Control System Facing Hurdles Ahead of October Delivery, GAO Says Next page： Planet Labs Unit Selected for Multiple Award NASA Contract

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

RTX's GPS Ground Control System Facing Hurdles Ahead of October Delivery, GAO Says

Sep 9, 2024

11:30 AM EDT, 09/09/2024 (MT Newswires) -- RTX (RTX) must meet additional criteria if it is to successfully deliver its ground network to control GPS satellites by the October target date, the Government Accountability Office said in a report Monday. The Department of Defense has worked for over two decades to modernize its GPS with a jam-resistant, more secure, military-specific...

Planet Labs Unit Selected for Multiple Award NASA Contract

Sep 9, 2024

10:43 AM EDT, 09/09/2024 (MT Newswires) -- Planet Labs (PL) said Monday that its Planet Federal subsidiary was selected for the NASA Commercial SmallSat Data Acquisition Program On-Ramp1 multiple award contract, which has a maximum potential value of $476 million for all contractors selected. The fixed-price, indefinite-delivery/indefinite-quantity contract extends through Nov. 15, 2028 and will cover services to provide commercial...

Update: Summit Therapeutics' Trial Shows Ivonescimab Significantly Improved Progression-Free Survival, Shares Rise

Sep 9, 2024

11:19 AM EDT, 09/09/2024 (MT Newswires) -- (Updates with the latest stock movement in the first paragraph.) Summit Therapeutics ( SMMT ) shares were up 60% in recent Monday trading after the company said Sunday its phase 3 trial for non-small cell lung cancer treatment showed improved survival rate compared with pembrolizumab monotherapy. The company said Sunday that data from...

Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients

Sep 9, 2024

Monday, Relay Therapeutics Inc. ( RLAY ) shared interim data for RLY-2608 from ReDiscover study, an ongoing first-in-human study, to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of RLY-2608 alone, in combination with fulvestrant, and combination with fulvestrant and ribociclib or atirmociclib (Pfizer Inc ( PFE )‘s selective CDK4 inhibitor). The data showed that despite heavy pre-treatment,...